L3VLUP
ProSign in

ISRG · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ISRGLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ISRG
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterISRGLLY
Q3 202020 holders, $19.6bn33 holders, $14.1bn
Q4 202019 holders, $21.4bn29 holders, $17.3bn
Q1 202126 holders, $18.3bn24 holders, $23.0bn
Q2 202133 holders, $23.2bn24 holders, $27.8bn
Q3 202131 holders, $23.9bn31 holders, $29.9bn
Q4 202134 holders, $26.0bn31 holders, $34.7bn
Q1 202227 holders, $21.0bn24 holders, $35.3bn
Q2 202235 holders, $13.0bn33 holders, $42.7bn
Q3 202232 holders, $11.1bn31 holders, $43.4bn
Q4 202226 holders, $15.6bn31 holders, $46.6bn
Q1 202332 holders, $14.4bn33 holders, $44.3bn
Q2 202333 holders, $20.2bn37 holders, $59.6bn
Q3 202340 holders, $17.0bn44 holders, $67.6bn
Q4 202338 holders, $20.0bn45 holders, $73.6bn
Q1 202432 holders, $23.6bn41 holders, $95.3bn
Q2 202429 holders, $27.0bn43 holders, $110bn
Q3 202431 holders, $28.4bn45 holders, $107bn
Q4 202434 holders, $30.3bn46 holders, $93.9bn
Q1 202542 holders, $28.7bn42 holders, $98.4bn
Q2 202539 holders, $30.6bn43 holders, $93.2bn
Q3 202541 holders, $23.6bn39 holders, $86.7bn
Q4 202541 holders, $35.8bn41 holders, $123bn
Q1 202640 holders, $29.0bn39 holders, $106bn
Q2 202635 holders, $24.5bn44 holders, $132bn
ISRG

Intuitive Surgical Inc

Holders
40
Reported value
$29.0bn
Buyers
26
Sellers
19

Breadth +7 among 91 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
LLY

Eli Lilly & Co

Holders
39
Reported value
$106bn
Buyers
25
Sellers
25

Breadth 0 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2026

Among the 45 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Both (34)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Arrowstreet Capital LP, Artisan Partners LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, ExodusPoint Capital Management LP, Fidelity (FMR LLC), GAMCO Investors Inc, Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Millennium Management LLC, Neuberger Berman Group LLC, Point72 Asset Management LP, Polen Capital Management LLC, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Tudor Investment Corp, Two Sigma Investments LP, Voloridge Investment Management LLC, Wellington Management Group LLP, Woodline Partners LP

Only ISRG (6)

Baillie Gifford & Co, Balyasny Asset Management LLC, Coatue Management LLC, Davidson Kempner Capital Management LP, Freestone Grove Partners LP, Verition Fund Management LLC

Only LLY (5)

Brevan Howard Capital Management LP, Caxton Associates LLP, Harris Associates LP, Soros Fund Management LLC, Walleye Capital LLC

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →